Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7213MR)

This product GTTS-WQ7213MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7213MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11247MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ4965MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ14238MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ11521MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ10756MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ3604MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ9911MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ10485MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-2951742
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW